Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills

    The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills

    FromCell & Gene: The Podcast

    Start listeningView podcast show

    The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills

    FromCell & Gene: The Podcast

    ratings:
    Length:
    29 minutes
    Released:
    Nov 9, 2023
    Format:
    Podcast episode

    Description

    Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
    Released:
    Nov 9, 2023
    Format:
    Podcast episode

    Titles in the series (76)

    Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.